MEDIF and LABS Related Headlines
Go Back- MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
- MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
- MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
- MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
- Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
- MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
- MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
- MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
- MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting
- Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees
- MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
- MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
- Apollo Capital releases MediPharm (LABS) activist plan
- Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company
MEDIF and LABS Related Press Releases
Go Back- MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
- MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
- MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
- MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
- Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
- MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
- MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
- MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
- MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting
- Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees
- MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
- MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
- Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company
